UnknownPhase 2

Clinical Trial Using Bone Marrow-derived Mononuclear Cells for Spinal Cord Injury

Vietnam30 participantsStarted 2016-09

Plain-language summary

The purpose of study is to determine whether autologous mononuclear cells deriving from the bone marrow are effective in the treatment of spinal cord injury.

Who can participate

Age range20 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients with spinal cord injuries classified as A-B on the ASIA impairment scale
✓. Patients injured 3 weeks to 1 year previously
✓. Patients with partial spinal cord injury demonstrated by diagnostic imaging
✓. Patients aged between 20 and 60 years at the acquisition of informed consent
✓. Patients who submitted written informed consent by themselves

Exclusion criteria

✕. Patients with a completely transected spinal cord
✕. Patients with central spinal cord injury
✕. Patients with organ failure with SOFA score of 3 points or higher
✕. Patients in whom hepatitis B, hepatitis C, human immunodeficiency virus infection, or leukemia infection cannot be denied
✕. Patients with malignant tumour or a history of malignant tumour within 5 years
✕. Patients with following disease/disorder:
✕. Patients who are participating in other clinical trials or who completed participation within 6 months
✕. Patients who are pregnant or possibly pregnant

What they're measuring

Safety profile and adverse effects of the procedure

Timeframe: 6 months from the time when patients receive the treatment

Trial details

NCT IDNCT02923817

SponsorDa Nang Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-12

Contact for this trial

Ba Ngoc Nguyen, MD

+84905238311 ba_neurosur@yahoo.com.vn

View on ClinicalTrials.gov More Spinal Cord Injuries trials